| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6159203 | The Journal of Urology | 2012 | 6 Pages |
Abstract
Higher representation of favorable risk factors in recent years may have partly contributed to the improvement in overall survival observed in more recent metastatic renal cell carcinoma clinical trials. These shifts could affect the outcome interpretation.
Keywords
mRCCTKIECoGULNMSKCCIFNInterferon-αSEER programoverall survivalUpper limit of normalRiskeastern cooperative oncology grouplactate dehydrogenaseLDHNeoplasm metastasisMemorial Sloan-Kettering Cancer CenterTyrosine kinase inhibitorPerformance statusMetastatic renal cell carcinomaCarcinoma, renal cellKidney
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Sujata Patil, Judith Manola, Paul Elson, Sylvie Negrier, Bernard Escudier, Tim Eisen, Michael Atkins, Ronald Bukowski, Robert J. Motzer,